---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-385331"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2026-09-08T20:54:32+00:00"
generated_at: "2026-09-08T20:56:14.413354+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Amylyx enters avexitide supply agreements with Bachem and Polypeptide; $30M upfront to Polypeptide

## Summary
- Paid or agreed $30M upfront fee to Polypeptide for capacity reservation under term sheet.
- Bachem Manufacturing Agreement begins 2028 with minimum annual purchase quantities of avexitide drug substance.
- Both suppliers are non-exclusive; Amylyx may use alternate manufacturers.
- Supply prices adjusted annually for labor, utilities, overhead; terms auto-renew after 5 years.
- Agreements cover commercial manufacturing of avexitide if regulatory approval is obtained.

## SEC filing metadata
- accession: 0001193125-26-385331
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2026-09-08T20:54:32+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000119312526385331/0001193125-26-385331-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000119312526385331/d160615d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-385331
- JSON: https://secwatch.observer/filing/0001193125-26-385331.json
- Plain text: https://secwatch.observer/filing/0001193125-26-385331.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.